ArticlePharmacoepidemiology and drug safety2025
Changes to Patterns of Oncology Medicine Dispensing in Response to the Onset of the COVID-19 Pandemic in Ireland: An Interrupted Time Series Analysis.
Article in Pharmacoepidemiology and drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe onset of the COVID-19 pandemic disrupted oncology healthcare provision in most countries. The purpose of this study is to examine how the onset of COVID-19 influenced changes in dispensing dynamics of systemic anti-cancer therapy (SACT) medications from four drug classes: (i) chemotherapeutics; (ii) immunotherapies; (iii) endocrine therapies; and (iv) targeted therapies.
methodsMonthly pharmacy claims data from community and hospital reimbursement schemes were extracted and analyzed using interrupted time series analysis (ITSA) and autoregressive integrated moving average (ARIMA) models with March 2020 as the first interruption.
resultsThirteen medications (65%) from across all four SACT classes were found to have increasing dispensing rates before March 2020 (3 chemotherapies, 3 endocrine therapies, 3 immunotherapies, and 4 targeted therapies). Nine (69.2%) of these 13 SACT medications had decreasing rates of dispensing post-March 2020 (100% of chemotherapies, 75% targeted therapies, 33% immunotherapies, and 66% endocrine therapies). Regardless of drug class, three (15%) medications showed increasing rates of dispensing post-March 2020. DISCUSSION: Most dispensed SACT medications examined demonstrated changes in dispensing, particularly immunotherapies, after the onset of COVID-19. Changes in dispensing may be associated with aspects of healthcare disruption and clinical decision making at the time to help mitigate adverse outcomes for cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.